<DOC>
	<DOC>NCT02800447</DOC>
	<brief_summary>1. To observe and compare the overall response rate (ORR) of baseline BEACOPP and ABVD regimens for patients with advanced Hodgkin's lymphoma. 2. To evaluate the safety of Natulan® in Chinese patients with advanced Hodgkin's lymphoma</brief_summary>
	<brief_title>Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol</brief_title>
	<detailed_description>This is a confirmatory open-label, randomized, controlled, multicenter study. Recruited subjects are to be randomized to treatment group and controlled group, with ratio of 1:1. Treatment group will accept baseline BEACOPP regimen, while controlled group will accept ABVD regimen. The study design consisted of a screening phase of 1 week, a treatment phase of 24 or 32 weeks, and a post treatment follow-up of at least 2 years.</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>The subject is of age 18~65, both male and female; Newly pathologically diagnosed with classical Hodgkin's lymphoma (lymphocyte depletion type, lymphocyte rich type, nodular sclerosing type, and mixed cellularity type), who had not accepted previous treatment; Had stage IIB, III or IV disease, as assessed by the Ann Arbor classification; ECOG≤2, life expectancy ≥3 month; A negative serum pregnancy test required for sexually active women of childbearing potential; The subject voluntarily gives written informed consent to participate in the study. Hematopoietic function: Leukocyte &lt;3,500/mm3（3.5×109/L） Neutrophils &lt;1,500/mm3（1.5×109/L） Platelets &lt;100,000/mm3（100×109/L） Intolerance to any of the active ingredients and/or excipients in the study medications; Severe central nervous system disorders and mental illness; Severe heart disease (congestive heart failure, uncontrolled hypertension, unstable coronary artery disease, or myocardial infarction, or severe arrhythmia). Echocardiography showed resting left ventricular ejection fraction (LVEF) &lt; 50%); History of severe lung disease; AST or ALT＞2.5×ULN，total bilirubin≥1.5×ULN，serum creatinine＞1.5×ULN (for subject with liver metastases: AST or ALT&gt;5xULN, total bilirubin ≥ 3xULN); Uncontrolled, systemic, active infection； Positive serology to HIV; HBsAg positive subjects can still be enrolled in the study, but researchers should follow "The consensus on the Treatment of Lymphoma with Hepatitis B Infections" to observe closely and/or provide prophylactic antiHBV therapy (as per investigator's decision); Other previous or concomitant malignancy, except for basal cell carcinoma and/or cervical carcinoma in situ; The subject is receiving an investigational drug, or has participated in an investigational study within 30 days prior to screening; The subject is pregnant or lactating; or subjects of childbearing potential (both women and man subjects) do not want to take effective contraceptive measures during study period or within 3 months after study completes; Investigators believe subjects not suitable to participate in the study for other reasons.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>